The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 30 to 39 weeks (7 to 10 months).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
108
ICON Early Phase Services, LLC
San Antonio, Texas, United States
RECRUITINGICON Early Phase Services, LLC
Salt Lake City, Utah, United States
NOT_YET_RECRUITINGLilly Centre for Clinical Pharmacology
Singapore, Singapore
NOT_YET_RECRUITINGPart A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Baseline through end of the Follow-up (Week 25)
Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Baseline through end of the Follow-up (Week 33)
Part A and C: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY4174794
Time frame: Predose on day 1 through end of the Follow-up Period (Week 25)
Part A and C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794
Time frame: Predose on day 1 through end of the Follow-up Period (Week 25)
Part B: PK: Maximum Observed Drug Concentration (Cmax) of LY4174794
Time frame: Predose on day 1 through end of the Follow-up Period (Week 33)
Part B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4174794
Time frame: Predose on day 1 through end of the Follow-up Period (Week 33)
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.